Metabolic Brain Disease

, Volume 19, Issue 1–2, pp 125–134 | Cite as

Single Photon Emission Computed Tomography (SPECT) in Obsessive–Compulsive Disorder Before and After Treatment with Inositol

  • P. D. Carey
  • J. Warwick
  • B. H. Harvey
  • D. J. Stein
  • S. Seedat
Article

Abstract

Inositol, a glucose isomer and second messenger precursor, regulates numerous cellular functions and has demonstrated efficacy in obsessive–compulsive disorder (OCD) through mechanisms that remain unclear. The effect of inositol treatment on brain function in OCD has not been studied to date. Fourteen OCD subjects underwent single photon emission computed tomography (SPECT) with Tc-99m HMPAO before and after 12 weeks of treatment with inositol. Whole brain voxel-wise SPM was used to assess differences in perfusion between responders and nonresponders before and after treatment as well as the effect of treatment for the group as a whole. There was 1) deactivation in OCD responders relative to nonresponders following treatment with inositol in the left superior temporal gyrus, middle frontal gyrus and precuneus, and the right paramedian post-central gyrus; 2) no significant regions of deactivation for the group as a whole posttreatment; and 3) a single cluster of higher perfusion in the left medial prefrontal region in responders compared to nonresponders at baseline. Significant reductions in the YBOCS and CGI—severity scores followed treatment. These data are only partly consistent with previous functional imaging work on OCD. They may support the idea that inositol effects a clinical response through alternate neuronal circuitry to the SSRIs and may complement animal work proposing an overlapping but distinct mechanism of action.

SPECT OCD inositol treatment brain-imaging 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

references

  1. Balla, T., Bondeva, T., and Varnai, P. (2000). How accurately can we image inositol lipids in living cells? Trends Pharmacol. Sci. 21:238-241.Google Scholar
  2. Barak, Y., Levine, J., Glasman, A., Elizur, A., and Belmaker, R.H. (1996). Inositol treatment of Alzheimers disease. Prog. Neuoropsychopharmacol. Biol. Psychiatry 20:729-735.Google Scholar
  3. Baxter, L.R., Schwartz, J.M., Bergman, K.S., Szuba, M.P., Guze, B.H., Mazziotta, J.C., Alazraki, A., Selin, C.E., Ferng, H.K., Munford, P., and Phelps, M.E. (1992). Caudate glucose metabolic rate changes in both drug and behaviour therapy for obsessive–compulsive disorder. Arch. Gen. Psychiatry 49:681-689.Google Scholar
  4. Benjamin, J., Levine, J., Fux, M., Aviv, A., Levy, D., and Belmaker, R.H. (1995). Double blind controlled trial of inositol treatment of panic disorder. Am. J. Psychiatry 52:1084-1086.Google Scholar
  5. Benkelfat, C., Nordahl, T.E., Semple, W.E., King, A.C., Murphy, D.L., and Cohen, R.M. (1990). Local cerebral glucose metabolic rates in obsessive–compulsive disorder. Arch. Gen. Psychiatry 47:840-848.Google Scholar
  6. Brink, C.B., Viljoen, S.L., de Kock, S.E., Stein, D.J., and Harvey, B.H. (2004). Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells. Met. Br. Dis. 19:61-80.Google Scholar
  7. Brody, A.L., Saxena, S., Schwartz, J.M., Stoessel, P.W., Maidment, K., Phelps, M.E., and Baxter, L.R. (1998). FDG-PET predictors of response to behavioural therapy and pharmacotherapy in obsessive-compulsive disorder. Psychiatry Res. 84:1-6.Google Scholar
  8. Chang, L. (1978). A method for attentuation correction in radionuclide computed tomography. Trans. Nucl. Sci. 25:638-643.Google Scholar
  9. De Groot, A., and Treit, D. (2002). Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Brain Res. 949(1–2):60-70.Google Scholar
  10. De Groot, A., and Treit, D. (2003). Septal GABAergic and hippocampal cholinergic systems interact in the modulation of anxiety. Neuroscience 117:493-501.Google Scholar
  11. Einat, H., and Belmaker, R.H. (2001). The effects of inositol treatment in animal models of psychiatric disorders. J. Affect. Disord. 62:113-121.Google Scholar
  12. First, M.B., Spitzer, M.B., Gibbon, R.L., and Williams, J.B.W. (1995). Structured Clinical Interview for DSM IV Axis I Disorders—Clinician Version, Biometrics Research Department. New York State Psychiatric Institute, New York.Google Scholar
  13. Fux, M., Benjamin, J., and Belmaker, R.H. (1999). Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: Double-blind cross-over study. Int. J. Neurpsychopharmacol. 2:193-195.Google Scholar
  14. Fux, M., Levine, J., Aviv, A., and Belmaker, R.H. (1996). Inositol treatment of obsessive–compulsive disorder. Am. J. Psychiatry 153:1219-1221.Google Scholar
  15. Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischman, R.L., Hill, C.L., Heninger, G.R., and Charney, D.S. (1989). The Yale-Brown Obsessive Compulsive Scale. Arch. Gen. Psychiatry 46:1006-1016.Google Scholar
  16. Greist, J.H., Jefferson, J.W., Kobak, K.A., Katzelnick, D.J., and Serlin, R.C. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive–compulsive disorder. Arch. Gen. Psychiatry 52:53-59.Google Scholar
  17. Guy, W. (1976). ECDU Assessment Manual for Psychopharmacology, revised 1976, National Institute of Mental Health, Psychopharmacology Research Branch, pp. 217–222, 313–331.Google Scholar
  18. Harvey, B.H., Brink, C.B., Seedat, S., and Stein, D.J. (2002). Defining the neuromolecular action of myo-inositol: Application to obsessive–compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 26:21-32.Google Scholar
  19. Hoehn-Saric, R., Pearlson, G.D., Harris, G.J., Machlin, S.R., and Camargo, E.E. (1991). Effects of fluoxetine on regional cerebral blood flow in obsessive–compulsive patients. Am. J. Psychiatry 148:1243-1245.Google Scholar
  20. Hoehn-Saric, R., Schlaepfer, T.E., Greenberg, B.D., McLeod, D.R., Pearlson, G.D., and Wong, S.H. (2001). Cerebral blood flow in obsessive–compulsive patients with major depression: Effect of treatment with sertraline or desipramine on treatment responders and nonresponders. Psychiatry Res. Neuroimaging 108:89-100.Google Scholar
  21. Hugo, F., van Heerden, B., Zungu-Dirwayi, N., and Stein, D.J. (1999). Functional brain imaging in obsessive–compulsive disorder secondary to neurological lesions. Depress. Anxiety 10:129-136.Google Scholar
  22. Jenike, M.A., and Brotman, A.W. (1984). The EEG in obsessive–compulsive disorder. J. Clin. Psychiatry 45(3):122-124.Google Scholar
  23. Khanna, S. (1988). Obsessive–compulsive disorder: Is there frontal lobe dysfunction? Biol. Psychiatry 24(5):602-613.Google Scholar
  24. Kwon, J.S., Kim, J.J., Lee, D.W., Lee, J.S., Lee, D.S., Kim, M.S., Lyoo, I.K., Cho, M.J., and Lee, M.C. (2003). Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive–compulsive disorder. Psychiatry Res. 122(1):37-47.Google Scholar
  25. Levine, J. (1997a). Controlled trials of inositol in psychiatry. Eur. Neuropsychopharmacol. 7:147-155.Google Scholar
  26. Levine, J., Aviram, A., Holan, A., Ring, A., Barak, Y., and Belmaker, R.H. (1997b). Inositol treatment of autism. J. Neural Transm. 104:307-310.Google Scholar
  27. Levine, J., Barak, Y., Gonsalves, M., Elizur, A., and Belmaker, R.H. (1995). Double blind study of inositol versus placebo in depression. Am. J. Psychiatry 152:792-794.Google Scholar
  28. Levine, J., Goldberger, I., Rapoport, A., Schwartz, M., Schields, C., Elizur, A., Belmaker, R.H., Shapiro, J., and Agam, G. (1994). CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in anergic schizophrenia. Eur. Neuropsychopharmacol. 4:487-490.Google Scholar
  29. Levine, J., Ring, A., Barak, Y., Elizur, A., Kofman, O., and Belmaker, R.H. (1996). Inositol may worsen attention deficit disorder with hyperactivity. Hum. Psychopharmacol. 10:481-484.Google Scholar
  30. Mataix-Cols, D., Cullen, S., Lange, K., Zelaya, F., Andrew, C., Amaro, E., Brammer, M.J., Williams, S.C.R., Speckens, A., and Phillips, M.L. (2003). Neural correlates of anxiety associated with obsessive–compulsive symptom dimensions in normal volunteers. Biol. Psychiatry 53(6):482-493.Google Scholar
  31. McGuire, P.K., Bench, C.J., Frith, C.D., Marks, I., Frackowiak, R.S., and Dolan, R.J. (1994). Functional neuroanatomy of obsessive–compulsive phenomena. Br. J. Psychiatry 164:459-468.Google Scholar
  32. Montgomery, S.A., and Asberg, M.A. (1979). A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:382-389.Google Scholar
  33. Nemets, B., Talesnick, B., Belmaker, R.H., and Levine, J. (2002). Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. World J. Biol. Psychiatry 3:147-149.Google Scholar
  34. Palatnik, A., Frolov, K., Fux, M., and Benjamin, J. (2001). Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J. Clin. Psychopharmacol. 21(3):335-339.Google Scholar
  35. Piggot, T.A., and Seay, S.M. (1999). A review of the efficacy of selective serotonin reuptake inhibitors in obsessive–compulsive disorder. J. Clin. Psychiatry 60(2):101-106.Google Scholar
  36. Rauch, S.L., Shin, L.M., Dougherty, D.D., Alpert, N.M., Fischman, A.J, and Jenike, M.A. (2002). Predictors of fluvoxamine response in contamination-related obsessive–compulsive disorder: A PET symptom provocation study. Neuropsychopharmacol. 27(5):782-791.Google Scholar
  37. Russell, A., Cortese, B., Lorch, E., Ivey, J., Banerjee, S.P., Moore, G.J., and Rosenberg, D.R. (2003). Localised functional neurochemical marker abnormalities in dorsolateral prefrontal cortex in pediatric obsessive–compulsive disorder. J. Child Adolesc. Psychopharmacol. 13(Suppl. 1):S31-S38.Google Scholar
  38. Saxena, S., Brody, A., Ho, M., Zohrabi, N., Maidment, K.M., and Baxter, L.R. (2003). Differential brain metabolic predictors of response to paroxetine in obsessive–compulsive disorder versus major depression. Am. J. Psychiatry 160:522-532.Google Scholar
  39. Saxena, S., Brody, A.L., Ho, M.L., Alborzan, S., Maidment, K.N., Zohrabi, I., Ho, M.K., Huang, S.C., Wu, H.M., and Baxter, L.R., Jr. (2002). Differential cerebral metabolic changes with paroxetine treatment of obsessive–compulsive disorder vs major depression. Arch. Gen. Psychiatry 59:250-261.Google Scholar
  40. Saxena, S., and Rauch, S.L. (2000). Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Pyschiatr. Clin. North Am. 23:563-586.Google Scholar
  41. Schwartz, J.M., Stoessel, P.W., Baxter, L.R., Martin, K.M., and Phelps, M.E. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive–compulsive disorder. Arch. Gen. Psychiatry 53:109-113.Google Scholar
  42. Seedat, S., and Stein, D.J. (1999). Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: An open label trial. Int. Clin. Psychopharmacol. 14:353-356.Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • P. D. Carey
    • 1
  • J. Warwick
    • 1
    • 2
  • B. H. Harvey
    • 3
  • D. J. Stein
    • 1
  • S. Seedat
    • 1
  1. 1.MRC Research Unit for Anxiety and Stress Disorders, Department of PsychiatryUniversity of StellenboschTygerbergSouth Africa
  2. 2.Department of Nuclear MedicineUniversity of StellenboschTygerbergSouth Africa
  3. 3.Division of PharmacologySchool of Pharmacy, North West UniversityPotchefstroomSouth Africa

Personalised recommendations